NASDAQ •
Healthcare •
Biotechnology •
Quote as of 05/04/2026 16:00
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization13,649 mln
Float61.38 mln
Earnings Date05/27/2026
Piotroski F-Score
5
/ 9
Neutral
Beneish M-Score
-2.14
Caution advised
1-Year Forecast
298
Strong upside
Relative Strength
18
/ 100
Significantly lagging
Debt / Equity
-5.35
Negative equity
Dividend Yield
0.00%
No dividend
Business Description
Founded in Denmark in 2006, Ascendis Pharma is a drug development company built around its proprietary TransCon technology, which is designed to improve how medicines work in the body. The company currently sells two approved treatments ? one for children with growth hormone deficiency and another for adults with a rare condition affecting calcium regulation. Beyond these products, Ascendis is advancing additional treatments for rare hormonal disorders and exploring new therapies in cancer care.
